Mesoblast (NASDAQ:MESO) Stock Rating Upgraded by StockNews.com

Mesoblast (NASDAQ:MESO) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.67.

Mesoblast Trading Up 9.2 %

Shares of Mesoblast stock opened at $7.21 on Tuesday. The firm has a market capitalization of $823.24 million, a PE ratio of -6.44 and a beta of 3.60. The firm’s 50 day moving average is $4.09 and its 200 day moving average is $2.84. Mesoblast has a 1 year low of $1.61 and a 1 year high of $10.24.

Institutional Investors Weigh In On Mesoblast

An institutional investor recently raised its position in Mesoblast stock. Lazari Capital Management Inc. raised its position in Mesoblast Limited (NASDAQ:MESO) by 9.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 94,034 shares of the company’s stock after purchasing an additional 8,000 shares during the period. Lazari Capital Management Inc. owned 0.06% of Mesoblast worth $116,000 as of its most recent filing with the SEC. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.